66) Preliminary evidence also suggests overall reduced GI complications with the COX-2 selective inhibitors compared with NS-NSAIDs, even with concomitant use of proton pump inhibitors.
Collectively, these studies demonstrate significantly reduced GI complications with COX-2 selective inhibitors, compared with NS-NSAIDs, and a reduction in potential fatalities resulting from GI complications.
It is also unknown whether the COX-2 selective inhibitors will demonstrate these same effects although studies show that agents in these drug classes may have different effects from each other, possibly unrelated to prostaglandin inhibition.
In this trial the authors set out to compare the upper gastrointestinal safety of COX-2 selective inhibitors versus traditional NSAIDs in a way that simulated standard clinical practice.
The MEDAL (Multinational Etoricoxib and Diclofenac Arthritis Long-term) programme provides a randomised comparison of the COX-2 selective inhibitor etoricoxib and the traditional NSAID diclofenac in 34 701 osteoarthritis and rheumatoid arthritis patients followed up for a mean duration of 18 months.
They found that there were significantly fewer upper gastrointestinal clinical events with the COX-2 selective inhibitor etoricoxib than with the traditional NSAID diclofenac due to a decrease in uncomplicated events, but not in the more serious complicated events.
COX-2 selective inhibitors selectively block the inflammation-producing COX-2 specific enzyme that is produced in arthritic joints, and unlike traditional NSAIDs, do not affect the COX-1 enzyme, which is important for protecting against gastrointestinal problems.
Basel, Switzerland -- Basel, Switzerland, June 20 /PRNewswire/ -- Data from key clinical Phase III studies presented for the first time at EULAR, the European League Against Rheumatism annual congress in Lisbon, demonstrate that Prexige(r) (lumiracoxib), a novel COX-2 selective inhibitor, provides effective relief of the symptoms of osteoarthritis (OA).